Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 406

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

TERT Promoter Mutations and Risk of Recurrence in Meningioma

Open access
Sahm, Felix, Schrimpf, Daniel, Olar, Adriana, Koelsche, Christian, Reuss, David, Bissel, Juliane, Kratz, Annekathrin, Capper, David, Schefzyk, Sebastian, Hielscher, Thomas, Wang, Qianghu, Sulman, Erik P., Adeberg, Sebastian, Koch, Arend, Okuducu, Ali Fuat, Brehmer, Stefanie, Schittenhelm, Jens, Becker, Albert, Brokinkel, Benjamin, Schmidt, Melissa, Ull, Theresa, Gousias, Konstantinos, Friederike, Almuth, Lamszus, Kessler, Katrin, Debus, Jürgen, Mawrin, Christian, Kim, Yoo-Jin, Simon, Matthias, Ketter, Ralf, Paulus, Werner, Aldape, Kenneth D., Herold-Mende, Christel, von Deimling, Andreas·2016·Journal of the National Cancer Institute

Abstract

The World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djv377

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 406

Metadata

Authors
Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., Wang, Q., Sulman, E. P., Adeberg, S., Koch, A., Okuducu, A. F., Brehmer, S., Schittenhelm, J., Becker, A., Brokinkel, B., Schmidt, M., Ull, T., Gousias, K., Friederike, A., Lamszus, K., Debus, J., Mawrin, C., Kim, Y.-J., Simon, M., Ketter, R., Paulus, W., Aldape, K. D., Herold-Mende, C., & von Deimling, A.
Venue
Journal of the National Cancer Institute
Published
2015-12-13
Volume
108
Issue
5
Pages
djv377
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2210813576
Cited by
406
References
15
FWCI
15.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TERT Promoter Mutations and Risk of Recurrence in Meningioma. https://app.cochat.ai/papers/10.1093/jnci/djv377
The paper
Sahm, F., Schrimpf, D., Olar, A., Koelsche, C., Reuss, D., Bissel, J., Kratz, A., Capper, D., Schefzyk, S., Hielscher, T., Wang, Q., Sulman, E. P., Adeberg, S., Koch, A., Okuducu, A. F., Brehmer, S., Schittenhelm, J., Becker, A., Brokinkel, B., . . . von Deimling, A. (2016). TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djv377

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.